BIIB Biogen Inc.

Healthcare

Price

$222.89

Intrinsic value

$84.09

Buy price

$67.27

Discount

-165.1%

Overvalued [LOW CF reliability]

Live signals (1)

Daily bars as of Oct 8, 2026

UCUptrend ContinuationBullish ↑
A strong bullish bar closing back into a rising 20/50-SMA stack - the uptrend resuming after a pullback to the moving averages.
Fired Oct 5, 20263 daily bars ago35.8% win rate · 1x profit factor

A pattern is reported for 5 bars after it fires (the sweet-spot fill window), so an older bar count means the entry has had longer to play out - not that the signal is stronger. Win rate and profit factor are the pattern's backtested averages across the S&P 500, not a forecast for this ticker.

DCF walkthrough

Near-term growth (g1)0.00%

Terminal growth (g2)3.50%

Years of g1 growth4

Discount rate9.00%

Margin of safety20.00%

Operating CF: $2,878,800,000.00
Total debt: $8,355,100,160.00
Cash & STI: $1,284,999,936.00
Shares out.: 148,700,000

Overvalued [LOW CF reliability]

Intrinsic value$84.09

Buy price (with MOS)$67.27

Current price$222.89

Discount to intrinsic value-165.1%

7-step quality scorecard

ROE quality

LOW

Average ROE: 11.9%
Current ROE: 7.1%
Minimum ROE: 7.1%

Debt quality

CONSERVATIVE

Debt / Equity: 0.46x

Moat proxy

WEAK_PROXY

Cash-flow reliability

LOW

Operating CF / Net income: 3.45x

Technical chart

Confluence: NONE (0/3)

Weekly candles, ~3 years. Yellow line: 10-week EMA. Dashed lines: Fibonacci retracement of the last 52-week swing. Green arrow: an active DR1 support reclaim (see Live signals above for when it fired).

Assumptions & data quality

Data source: yfinance
Growth (g1) source: revenueCAGR
Valuation model: DCF_OCF
Debt as % of DCF PV: 42.7%
Public economic interest: 100.0%

These are model outputs built on assumptions (growth rate, discount rate, margin of safety), not facts - trust but verify, especially for LOW cash-flow-reliability or UNKNOWN-quality rows.